Meningococcal infection

References

1. Abbot J. D., Jones D. M., Painter M. J., Young S. E. J. 1985; The epidemiology of meningococcal infection in England and Wales 1912–1983. Journal of Infection 11:241–257
   [Google Scholar]
2. Abdillahi H., Crowe B. A., Achtman M., Poolman J. Two monoclonal antibodies which recognize the serotype 4 antigen of Neisseria meningitidis. European Journal of Clinical Microbiology in press
   [Google Scholar]
3. Abdillahi H., Poolman J. T. 1987; Typing of group B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. FEMS 48:367–371
   [Google Scholar]
4. Abdillahi H., Poolman J. T., Hopman C. T. P., Zanen H. C. 1986; Sero- and subtyping of non-2a, non-2b and non-15 group B Neisseria meningitidis. Antonie van Leeuwenhoek 52:242–244
   [Google Scholar]
5. Achtman M. 1988; Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A. Journal of Experimental Medicine in press
   [Google Scholar]
6. Achtman M., Pluschke G. 1986; Clonal analysis of descent and virulence among selected Escherichia coli. Annual Review of Microbiology 40:185–210
   [Google Scholar]
7. Barlow A. K., Heckels J. E., Clarke I. N. 1987; Molecular cloning and expression of Neisseria meningitidis class 1 outer membrane protein in Escherichia coli K-12. Infection and Immunity 55:2734–2740
   [Google Scholar]
8. Barritt D. S., Schwalbe R. S., Klapper D. G., Cannon J. G. 1987; Antigenic and structural differences among six proteins II expressed by a single strain of Neisseria gonorrhoeae. Infection and Immunity 55:2026–2031
   [Google Scholar]
9. Beuvery E. C., Miedema F., van Delft R., Haverkamp J. 1983; Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infection and Immunity 40:39–45
   [Google Scholar]
10. Blackwell C. C., Jonsdottir K., Mohammed J., Weir D. M. 1986; Non-secretion of blood group antigens: a genetic factor predisposing to infection by Neisseria meningitidis. Proceedings of the fifth international pathogenic neisseria conference V p 106
    [Google Scholar]
11. Blakebrough I. S., Gilles H. M. 1980; The effect of rifampicin on meningococcal carriage in family contacts in northern Nigeria. Journal of Infection 2:137–143
    [Google Scholar]
12. Blakebrough I. S., Greenwood B. M., Whittle H. C., Bradley A. K., Gilles H. M. 1982; The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. Journal of Infectious Diseases 146:626–637
    [Google Scholar]
13. Branham S. E. 1953; Serological relationships among meningococci. Bacteriological Reviews 17:175–188
    [Google Scholar]
14. Caugant D. A. 1986a; Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. Journal of General Microbiology 132:641–652
    [Google Scholar]
15. Caugant D. A. 1986b; Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proceedings of the National Academy of Sciences of the USA 83:4927–4931
    [Google Scholar]
16. Caugant D. A., Mocca L. F., Frasch C. E., Froholm L. O., Zollinger W. D., Selander R. K. 1987; Genetic structure of Neisseria meningitidis populations in relation to serogroup, and outer membrane protein pattern. Journal of Bacteriology 169:2871–2792
    [Google Scholar]
17. Crowe B. 1986; Clonal analysis of Neisseria meningitidis serogroup A. Proceedings of the fifth international pathogenic neisseria conference, I. p 14
18. Dalhoff A. 1985; Differences between bacteria grown in vitro and in vivo. Journal of Antimicrobial Chemotherapy 15: Suppl A175–195
    [Google Scholar]
19. de Lemos R. A., Haggerty R. J. 1969; Corticosteroids was an adjunct to treatment in bacterial meningitis: a controlled clinical trial. Pediatrics 44:30–34
    [Google Scholar]
20. Densen P., Weiler J. M., Griffiss J., Hoffman L. G. 1987; Familial properdin deficiency and fatal meningococcaemia. New England Journal of Medicine 316:922–926
    [Google Scholar]
21. De Wals P. 1981; Meningococcal disease in Belgium: secondary attack rate among household, day-care nursery, and pre-elementary school contacts. Journal of Infection 3: Suppl 153–61
    [Google Scholar]
22. Edwards E. A., Devine L. F., Sengbusch C. H., Ward H. W. 1977; Immunologic investigations of meningococcal disease: brevity of Group C acquisition prior to disease occurrence. Scandinavian Journal of Infectious Diseases 9:105–110
    [Google Scholar]
23. Eskola J. 1985; Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine. Lancet 1:1184–1186
    [Google Scholar]
24. Fallon R. J., Brown W. M., Lore W. 1984; Meningococcal infections in Scotland 1972–82. Journal of Hygiene 93:167–180
    [Google Scholar]
25. Ferguson J. H., Chapman O. D. 1948; Fulminating meningococcic infections and the so-called Waterhouse-Friderichsen syndrome. American Journal of Pathology 24:763–796
    [Google Scholar]
26. Filice G. A., Hayes P. S., Counts G. W., Griffiss J. M., Fraser D. W. 1985; Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora. Journal of Clinical Microbiology 22:152–156
    [Google Scholar]
27. Finne J., Leinonen M., Makela P. H. 1983; Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2:355–357
    [Google Scholar]
28. Fothergill L. D., Wright J. 1933; Influenzal meningitis: relation of age incidence to bactericidal power of blood against causal organism. Journal of Immunology 24:273–281
    [Google Scholar]
29. Frasch C. E. 1977; Role of protein serotype antigens in protection against disease due to Neisseria meningitidis. Journal of Infectious Diseases 136: (Suppl) S84–S90
    [Google Scholar]
30. Frasch C. E., McNelis R. M., Gotschlich E. C. 1976; Strain-specific variation in the protein and lipopolysaccharide composition of the group B meningococcal outer membrane. Journal of Bacteriology 127:973–981
    [Google Scholar]
31. Frasch C. E., Coetzee G., Zahradrik D. M., Wang L. K. 1985a; New developments in meningococcal vaccines. In Schoolnik G. K. (ed) The pathogenic neisseriae American Society for Microbiology; Washington, DC: pp 633–639
    [Google Scholar]
32. Frasch C. E., Zollinger W. D., Poolman J. T. 1985b; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Reviews of Infectious Diseases 7:504–510
    [Google Scholar]
33. Froholm L. O. 1986; Preliminary results from a clinical trial with a meningococcal vaccine containing serotype 2b and 15 antigens in complex with mixed, A. C, K and W135 polysaccharides. Antonie van Leeuwenhoek 52:239–241
    [Google Scholar]
34. Gerard P., Moriau M., Bachy A., Malvaux P., DeMeyer R. 1973; Meningococcal purpura: report of 19 patients treated with heparin. Pediatrics 82:780–786
    [Google Scholar]
35. Goldschneider I., Gotschlich E. C., Artenstein M. S. 1969; Human immunity to the meningococcus. I. The role of humoral antibodies. Journal of Experimental Medicine 129:1307–1326
    [Google Scholar]
36. Gotschlich E. C., Austrian R., Cvjetanovic B., Robbins J. B. 1978; Prospects for the prevention of bacterial meningitis with polysaccharide vaccines. Bulletin of the WHO 56:509–518
    [Google Scholar]
37. Gotschlich E. C., Fraser B. A., Nishimura O., Robbins J. B., Liu T. Y. 1981; Lipid on capsular polysaccharides of gram-negative bacteria. Journal of Biological Chemistry 256:8915–8921
    [Google Scholar]
38. Gotschlich E. C., Goldschneider I., Artenstein M. S. 1969; Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. Journal of Experimental Medicine 129:1367–1384
    [Google Scholar]
39. Gotschlich E. C., Liu T. Y., Artenstein M. S. 1969; Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group, A. group, B. and group C meningococcal polysaccharides. Journal of Experimental Medicine 129:1349–1365
    [Google Scholar]
40. Greenfield S., Sheehe P. R., Feldman H. A. 1971; Meningococcal carriage in a population of “normal” families. Journal of Infectious Diseases 123:67–73
    [Google Scholar]
41. Greenwood B. M. 1987; Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa. Journal of Infection 14:167–184
    [Google Scholar]
42. Greenwood B. M., Whittle H. C., Bryceson A. D. M. 1973; Allergic complications of meningococcal disease. II. Immunological investigations. British Medical Journal 269:737–740
    [Google Scholar]
43. Greenwood B. M., Whittle H. C., Dominic–Rajkovic O. 1971; Counter-current immunoelectrophoresis in the diagnosis of meningococcal infections. Lancet 2:519–521
    [Google Scholar]
44. Griffiss J., Bertram M. A. 1977; Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease. Journal of Infectious Diseases 136:733–739
    [Google Scholar]
45. Griffiss J. McL 1982; Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Reviews of Infectious Diseases 4:159–172
    [Google Scholar]
46. Hall C. J., Nelder C., Melville C. A. S. 1985; Listeriosis. British Medical Journal 291:608
    [Google Scholar]
47. Hankins W. A., Gwaltney J. M., Hendley J. O., Farquar J. D., Samuelson J. S. 1982; Clinical and serological evaluation of a meningococcal polysaccharide vaccine, Groups A, C, Y and W 135.. Proceedings of the Society for Experimental Biology and Medicine 169:54–57
    [Google Scholar]
48. Heckels J. E., Virji M. 1985; Monoclonal antibodies against gonococcal pili: uses in the analysis of gonococcal immunochemistry and virulence. In de Macario A. J. L., de Macario E. C. (eds) Monoclonal antibodies against bacteria vol I Academic Press Inc; New York: pp 1–35
    [Google Scholar]
49. Heist G. D., Cohen S., Solis-Cohen M. 1922; A study of the virulence of meningococci for man and of human susceptibility to meningococcic infection. Journal of Immunology 7:1
    [Google Scholar]
50. Hobbs J. R., Milner R. D. G., Watt P. S. 1967; Gamma-M deficiency predisposing to meningococcal septicaemia. British Medical Journal 4:583–586
    [Google Scholar]
51. Jennings H. J., Roy R., Michon P. 1985; Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. Journal of Immunology 134:2651–2657
    [Google Scholar]
52. Jennings H. J., Gamian A., Ashton F. E. 1987; N–propionylated group B meningococcal polysaccharide mimics a unique epitope on group B meningococci. Journal of Experimental Medicine 165:1207–1211
    [Google Scholar]
53. Jones D. M., Eldridge J., Sutcliffe E. M. 1986; Emergence of group B type 15 strains as a cause of meningococcal infection in England and Wales. Antonie van Leeuwenhoek 52:206–207
    [Google Scholar]
54. Kaiser A. B., Hennekens C. H., Saslaw M. S., Hayes P. S., Bennett J. V. 1974; Seroepidemiology and chemoprophylaxis of disease due to sulfonamide-resistant Neisseria meningitidis in a civilian population. Journal of Infectious Diseases 130:217223
    [Google Scholar]
55. Käyhty H., Karanko V., Peltola H., Sama S., Makela P. H. 1980; Serum antibodies to capsular polysaccharide vaccine of Group A Neisseria meningitidis followed for three years in infants and children. Journal of Infectious Diseases 142:861–868
    [Google Scholar]
56. Lapeyssonnie L. 1963; La meningite cerebrospinale en Afrique. Bulletin of the WHO 28: Suppl 3–114
    [Google Scholar]
57. Makela P. H. 1977; Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. Journal of Infectious Diseases 136: Suppl S43–S50
    [Google Scholar]
58. Maniatis T., Fritsch E. F., Sambrook J. 1982; Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor; NY:
    [Google Scholar]
59. Manios S. G., Manakoudi F., Maniati E. 1971; Fulminant meningococcemia. Heparin therapy and survival rate. Scandinavian Journal of Infectious Diseases 3:127–133
    [Google Scholar]
60. Margaretten W., Csavassy I., McKay D. G. 1967; An electron microscope study of a case of meningococcemia in man. American Journal of Diseases of Children 114:268–277
    [Google Scholar]
61. Meningococcal Disease Surveillance Group 1976; Meningococcal disease: secondary attack rate and chemoprophylaxis in the United States 1974. Journal of the American Medical Association 235:261–265
    [Google Scholar]
62. Mocca L. F., Karpas A. B., Wu L. H., Frasch C. E. 1984; Functional activity of monoclonal antibodies against outer membrane surface antigens of Neisseria meningitidis. Proceedings of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, p 295 (abstract)
63. Nicholson A., Lepow J. H. 1979; Host defence against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science 205:298–299
    [Google Scholar]
64. Olcen P., Kjellander J., Daniellsson D., Lindquist B. L. 1981; Epidemiology of Neisseria meningitidis prevalence and symptoms from the upper respiratory tract in family members to patients with meningococcal disease. Scandinavian Journal of Infectious Diseases 13:105–109
    [Google Scholar]
65. Olyhoek T., Crowe B. A., Achtman M. 1985; Epidemiological analyses of the geographical distribution of Neisseria meningitidis group A. In Schoolnik G. K. (ed) The pathogenic neisseriae American Society for Microbiology; Washington DC: pp 530–535
    [Google Scholar]
66. Olyhoek T., Crowe B. A., Achtman M. 1987; The clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Reviews of Infectious Diseases 9:665–692
    [Google Scholar]
67. Olyhoek T., Crowe B. A., Wall B., Achtman M. 1988; Comparison of clonal analysis and DNA restriction analysis for typing of Neisseria meningitidis. Microbial Pathogenesis 4:45–51
    [Google Scholar]
68. Orchard R. T., Cramb M., Parkins R. A. 1972; Chronic meningococcal septicaemia. Infection 209:338–339
    [Google Scholar]
69. Peltola H. 1983; Meningococcal disease: still with us. Reviews of Infectious Diseases 5:71–91
    [Google Scholar]
70. Peltola H. 1977; Clinical efficacy of meningococcal group A vaccine in children three months to five years of age. New England Journal of Medicine 297:686–691
    [Google Scholar]
71. Pinals R. S., Ropes M. W. 1964; Meningococcal arthritis. Arthritis and Rheumatism 7:241–258
    [Google Scholar]
72. Poolman J. T., Buchanan T. M. 1983; Monoclonal antibodies against meningococcal outer membrane proteins. Medicine Tropical 43:139–142
    [Google Scholar]
73. Poolman J. T., de Marie S., Zanen H. C. 1980; Variability of low-molecular-weight, heat-modifiable outer membrane proteins of Neisseria meningitidis. Infection and Immunity 30:642–648
    [Google Scholar]
74. Poolman J. T., Hopman C. T. P., Zanen H. C. 1985a; Colony variants of Neisseria meningitidis strain 2996 (B: 2b: P12): influence of class-5 outer membrane proteins and lipopolysaccharides. Journal of Medical Microbiology 19:203–209
    [Google Scholar]
75. Poolman J. T., Lind I., Jonsdottir K., Forholm L. O., Jones D. M., Zanen H. C. 1986; Meningococcal serotypes and serogroup B disease in North-West Europe. Lancet 2:555–558
    [Google Scholar]
76. Poolman J. T., Wientjes F. B., Hopman C. T. P., Zanen H. C. 1985b; Influence of the length of lipopolysaccharide molecules on the surface exposure of class 1 and 2 outer membrane proteins of Neisseria meningitidis 2996 (B: 2b: PI.2). In Schoolnik G. K. (ed) The pathogenic neisseriae American Society for Microbiology; Washington DC: pp 562–570
    [Google Scholar]
77. Poolman J. T., Zanen H. C. 1980; Antibody development after meningococcal disease as measured by gel-immuno-radioassay (GIRA). In Daniellsson D., Normark S. (eds) Genetics and immunobiology of pathogenic neisseria Umea University Press; pp 107–115
    [Google Scholar]
78. Poolman J. T. 1987; Comparison of meningococcal outer membrane protein vaccines, solubilized with detergent or C polysaccharide. Antonie van Leeuwenhoek Si AM-AW
    [Google Scholar]
79. Ross S. C., Densen P. 1984; Complement deficiency states and infection; epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 63:243–273
    [Google Scholar]
80. Ross S. C., Rosenthal P. J., Berberich H. M., Densen P. 1987; Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. Journal of Infectious Diseases 155:1266–1275
    [Google Scholar]
81. Saukkonen K., Abdillahi H., Poolman J. T., Leinonen M. 1987; Protective efficacy of monoclonal antibodies to class 1 and 3 outer membrane proteins of Neisseria meningitidis B: 15: PI. 16 in infant rat infection model. New prospects for vaccine development. Microbial Pathogenesis 3:261–268
    [Google Scholar]
82. Selander R. K., Caugant D. A., Ochman H., Musser J. M., Gilmour M. N., Whittman T. S. 1986; Methods of multilocus enzyme electrophoresis for bacterial population genetics and sys-tematics. Applied and Environmental Microbiology 51:873884
    [Google Scholar]
83. Selander R. K., Musser J. M., Caugant D. A., Gilmour M. A., Whittman T. S. 1987; Population genetics of pathogenic bacteria. Microbial Pathogenesis 3:1–7
    [Google Scholar]
84. Severin W. P. J. 1972; Latex agglutination in the diagnosis of meningococcal infection. Journal of Clinical Pathology 25:1079–1082
    [Google Scholar]
85. Slawig B. 1986; Antigen-spezifitat von Serum-Antikorpern in Bezug auf die Zelloberflache von Neisseria meningitidis der Serogruppe A. Freie Universitat, Fachbereich Biologie; Berlin: pp 1–114
    [Google Scholar]
86. Stern A., Meyer T. F. 1987; Common mechanism controlling phase and antigenic variation in pathogenic neisseriae. Molecular Microbiology 1:5–12
    [Google Scholar]
87. Swanson J., King G. 1978; Neisseria gonorrhoeae granulocyte interactions. In Brooks C. F. (ed) Immunobiology of Neisseria gonorrhoeae American Society for Microbiology; Washington DC: pp 221–226
    [Google Scholar]
88. Tinsley C. R., Heckels J. E. 1986; Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection. Journal of General Microbiology 132:2483–2490
    [Google Scholar]
89. Tsai Frasch C. E., Mocca L. F. 1981; Five structural classes of major outer membrane proteins in Neisseria meningitidis. Journal of Bacteriology 146:69–78
    [Google Scholar]
90. VanPutten J. M. P., Linders M. T., Weel J. F. L., Poolman J. T. 1987; Differential expression of Fe-repressible and growth-rate-sensitive proteins in Neisseria meningitidis and Neisseria gonorrhoeae. Antonie van Leeuwenhoek 53:557–564
    [Google Scholar]
91. Virji M., Heckels J. E. 1983; Antigenic cross-reactivity of Neisseria pili: investigations with type- and species-specific monoclonal antibodies. Journal of General Microbiology 129:2761–2768
    [Google Scholar]
92. Virji M., Heckels J. E., Watt P. J. 1983; Monoclonal antibodies to gonococcal pili: studies on antigenic determinants on pili from variants of strain P9. Journal of General Microbiology 129:1965–1973
    [Google Scholar]
93. Virji M., Zak K., Heckels J. E. 1985; Use of monoclonal antibodies to detect common protein antigens present in outer membranes of Neisseria species. In Schoolnik G. K. (ed) The pathogenic neisseriae American Society for Microbiology; Washington DC: pp 276–280
    [Google Scholar]
94. Vieusseaux M. 1805; Memoire sur le maladie qui a regne a Geneve au printemps de 1805. Journal de Medicine, Chirurgie et Pharmacie II:163–165
    [Google Scholar]
95. Wedege E., Michaelsen T. E. 1987; Human immunoglobin G subclass immune response to outer membrane antigens in meningococcal group B vaccine. Journal of Clinical Microbiology 25:1349–1353
    [Google Scholar]
96. Weichselbaum A. 1887; Uber die aeriologie der akuten meningitis cerebrospinalis. Fortschritte der Medecin 5:573–575
    [Google Scholar]
97. Wenzel R. P., Davies J. A., Mitzel J. R., Beam W. E. 1973; Non usefulness of meningococcal carriage-rates. iMncet 2:205
    [Google Scholar]
98. Whittle H. C. 1973; Allergic complications of meningococcal disease I—clinical aspects. British Medical Journal 269:733–737
    [Google Scholar]
99. Wyle F. A. 1972; Immunologic response of man to group B meningococcal polysaccharide vaccines. Journal of Infectious Diseases 126:514–522
    [Google Scholar]
100. Zollinger W. D., Mandrell R. E. 1980; Type-specific antigens of group A Neisseria meningitidis: lipopolysaccharide and heat-modifiable outer-membrane proteins. Infection and Immunity 28:451–458
     [Google Scholar]
101. Zollinger W. D., Mandrell R. E., Altieri P., Berman S., Lowenthal J., Artenstein M. S. 1978; Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. Journal of Infectious Diseases 137:728–739
     [Google Scholar]
102. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. 1979; Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. Journal of Clinical Investigation 63:836–848
     [Google Scholar]
103. Zollinger W. D., Moran E. E., Connelly H., Mandrell R. E., Brant R. 1984; Monoclonal antibodies to serotype 2 and serotype 15 outer membrane proteins of Neisseria meningitidis and their use in serotyping. Infection and Immunity 46:260–266
     [Google Scholar]
104. Zollinger W. D., Pennington C. L., Artenstein M. S. 1974; Human antibody response to three meningococcal outer membrane antigens: comparison by specific haemagglutination assay. Infection and Immunity 10:975–984
     [Google Scholar]